Significant Ownership of Merck & Co., Inc.

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for Merck & Co., Inc. focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ Kelly Grez - Kelly Grez/Corporate Secretary
Manager location
Rahway, NJ

Follow Filing Activity

Follow Merck & Co., Inc. and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Significant Ownership of Merck & Co., Inc.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
EVAX Evaxion Biotech A/S American Depositary Shares, each representing fifty Ordinary Shares, DKK 0.25 nominal value per share 20% $105,531,938 63,004,142 Merck & Co., Inc. 31 Jan 2025
PSNL Personalis, Inc. Common Stock, $0.0001 par value per share 16% $53,792,132 14,044,943 Merck & Co., Inc. 19 Dec 2024

Schedules 13D/G Reported by Merck & Co., Inc.:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .